Product Description:

• ALECENSA is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

How to use:

• 600 mg orally twice daily. Administer ALECENSA with food.

Caution & Warnings:

• Hepatotoxicity
• Interstitial Lung Disease (ILD)/Pneumonitis
• Renal Impairment
• Bradycardia
• Severe Myalgia and Creatine Phosphokinase (CPK) Elevation
• Hemolytic Anemia
• Embryo-Fetal Toxicity

Side Effects:

• fatigue, constipation, edema, myalgia, and anemia.

Ingredients:

• Alectinib 150Mg.